NORTHWEST BIOTHERAPEUTICS INC — fact timeline

NORTHWEST BIOTHERAPEUTICS INC completed an acquisition involving Toucan Holdings LLC for purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for (closed 2025-10-24).

“with potential acceleration after regulatory approval of the Company’s DCVax®-L product. The consideration for the acquisition consists of a purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for manufacturing and related services already provided under”

NORTHWEST BIOTHERAPEUTICS INC: Increased authorized shares of common stock from 1,700,000,000 to 2,600,000,000 (effective 2025-12-30).

“On December 30, 2025, the Company filed a Certificate of Amendment of its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of the State of Delaware, which effected an increase in the Company’s authorized shares of common stock, from 1,700,000,000 to 2.600,000,000, par value $0.001 per share.”

NORTHWEST BIOTHERAPEUTICS INC incurred convertible notes of $5 million with YA II PN, Ltd. at no interest maturing 12 months.

“On November 14, 2025 the Company entered into a $5 million convertible Promissory Note financing (the “Note”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”).”

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $5,505,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.

“On October 27, 2025, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $5,505,000.”

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.

“On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.”

NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2024-04-26).

“On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.”

Pat Sarma was appointed as Class II director at NORTHWEST BIOTHERAPEUTICS INC.

“The Board appointed Pat Sarma as a Class II director on March 18, 2024, and also appointed him to the Audit, Compensation, and Conflicts Committees of the Board.”

Jerry Jasinowski retired as Director at NORTHWEST BIOTHERAPEUTICS INC.

“Mr. Jerry Jasinowski retired from the Board of Directors of Northwest Biotherapeutics, Inc. on March 8, 2024, after more than a decade of service on the Board.”

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 24 months.

“On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 24 months. Repayments do not start until November 10, 2024. Following November 10, 2024, the Loan Agreement will be amortized in 12 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent.”

NORTHWEST BIOTHERAPEUTICS INC entered into Commercial Loan Agreement and Note with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-11-10).

“On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.”

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.

“On March 2, 2023, Northwest Biotherapeutics, Inc. (the "Company") entered into a Commercial Loan Agreement and Note (collectively, the "Loan Agreement") with Streeterville Capital, LLC (the "Holder") in the amount of $11,005,000.”

NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-03-02).

“On March 2, 2023, Northwest Biotherapeutics, Inc. (the "Company") entered into a Commercial Loan Agreement and Note (collectively, the "Loan Agreement") with Streeterville Capital, LLC (the "Holder") in the amount of $11,005,000.”

NORTHWEST BIOTHERAPEUTICS INC: Increased authorized shares of common stock from 1,200,000,000 to 1,700,000,000 (effective 2023-01-09).

“On January 9, 2023, the Company filed a Certificate of Amendment of its Seventh Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of the State of Delaware, which effected an increase in the Company’s authorized shares of common stock, from 1,200,000,000 to 1,700,000,000, par value $0.001 per share.”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 1,200,000,000 to 1,700,000,000 at the 2022-12-30 meeting.

“The votes for approval by the common and preferred stockholders, voting together as a single class, as a percentage of votes cast, and as a percentage of the total outstanding shares of Common and Preferred Stock combined as of the record date, were as follows: For Against Abstained Broker Non-Votes Common Stock Increase Amendment 799,877,480 37,214,287 4,132,144 0 Percent of votes cast (95.1%) (4.4%) (0.5%) Percent of total Common & Preferred Stock (74.3%) (3.5%) (0.4%)”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of previously reported 2020 option awards to the Company's independent directors at the 2022-12-30 meeting.

“The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2020 Option Awards to the Company's Independent Directors 619,934,754 (90.4%) 65,686,803 (9.6%) 8,392,803 (N/A) 147,209,551 (N/A)”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Advisory vote on 2021 executive compensation at the 2022-12-30 meeting.

“The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2021 Executive Compensation 625,747,069 (91.9%) 55,153,546 (8.1%) 13,113,745 (N/A) 147,209,551 (N/A)”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of the same option awards made in 2020 to the Company's named executive officers at the 2022-12-30 meeting.

“The votes for ratification were as follows: For Against Abstained Broker Non-Votes Ratification of Named Executive Officer Option Awards 613,009,482 (90.0%) 68,146,624 (10.0%) 12,858,254 (N/A) 147,209,551 (N/A)”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of Appointment of Cherry Bekaert LLP as the independent registered public accounting firm at the 2022-12-30 meeting.

“The votes for appointment of Cherry Bekaert were as follows: For Against Abstained Broker Non-Votes Ratification of Cherry Bekaert LLP 829,094,918 (98.8%) 9,951,520 (1.2%) 2,177,473 (N/A) 0”

NORTHWEST BIOTHERAPEUTICS INC shareholders approved Election of Directors at the 2022-12-30 meeting.

“The votes for Ms. Powers and Dr. Malik were as follows: For Withheld Broker Non-Votes Ms. Linda F. Powers 674,562,624 (97.2%) 19,451,736 (2.8%) 147,209,551 (N/A) Dr. Navid Malik 676,764,972 (97.5%) 17,249,388 (2.5%) 147,209,551 (N/A)”